✦ LIBER ✦

Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma

✍ Scribed by William N. William Jr; James Uyeki; Faye M. Johnson; Lei Feng; Beverly O. Peeples; Frank V. Fossella; Daniel D. Karp; George R. Blumenschein; David J. Stewart; Bonnie S. Glisson

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 171 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25076

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Alternating chemotherapy with etoposide

Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma : A Phase II trial of the North Central Cancer Treatment Group

✍ James R. Jett; Alan K. Hatfield; Shauna Hillman; Michael D. Bauman; James A. Mai 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to test the response rate and toxicity of alternating chemotherapy in previously untreated patients with extensive‐stage small cell lung carcinoma (SCLC). ## METHODS Patients with histologically proven, extensive‐stage SCLC, with a perfor

High dose tamoxifen plus cisplatin and e

High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma

✍ Chih-Hsin Yang; Ann-Lii Cheng; Kun-Huei Yeh; Chong-Jen Yu; Jing-Fang Lin; Pan-Ch 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## BACKGROUND. Tamoxifen sensitizes cancer cells to chemotherapeutic agents. High dose tamoxifen has been tested in the treatment of patients with melanoma and other cancers. The authors conducted a Phase II study of high dose tamoxifen plus cisplatin and etoposide for patients with advanced, inop

A multicenter, randomized, Phase II stud

A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma

✍ Filippo De Marinis; Fabrizio Nelli; Marco Lombardo; Francesco Ferraú; Santi Barb 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to evaluate the activity and toxicity of combined cisplatin, etoposide, and gemcitabine (PEG) and combined cisplatin plus gemcitabine (PG) in previously untreated patients with extensive‐stage and poor‐prognosis limited‐stage small‐cell lun

Phase I studies of imatinib mesylate com

Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma

✍ Faye M. Johnson; Lee M. Krug; Hai T. Tran; Stephanie Shoaf; Victor G. Prieto; Ph 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 329 KB 👁 2 views

A Phase II study of all-trans-retinoic a

A Phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma : An Eastern Cooperative Oncology Group study

✍ Gregory P. Kalemkerian; Michael Jiroutek; David S. Ettinger; John A. Dorighi; Da 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

Alternated approach with local irradiati

Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer

✍ Cécile le Péchoux; Rodrigo Arriagada; Thierry Le Chevalier 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 226 KB 👁 2 views